Syntaxin receives £18m investment

Syntaxin's series-B investors – Abingworth, SR One, Life Science Partners, Johnson & Johnson Development Corporation and Quest – also participated in the latest round.

Syntaxin, launched in 2005, is a biopharmaceutical company based in Abingworth. Its lead product is the Targeted Secretion Inhibitor (TSI) technology platform. The funding will be used for the development of the TSI and clinical proof-of-concept studies for its acromegaly programme.

The unquote" team is currently researching this transaction. In-depth deal information for subscribers will follow shortly.

If you have any information regarding this transaction, please contact Diana Petrowicz on +44 20 7004 7505 or diana.petrowicz@incisivemedia.com

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• UK / Ireland
• Healthcare
• Early-stage
• Abingworth Management
• Life Science Partners